Altmetrics
Downloads
104
Views
50
Comments
0
A peer-reviewed article of this preprint also exists.
supplementary.zip (31.39KB )
This version is not peer-reviewed
Submitted:
29 February 2024
Posted:
29 February 2024
You are already at the latest version
Variables | Whole sample (N = 200) | Symptoms duration of less than 6 hours (N = 100) | Symptoms duration of more than 6 hours (N = 100) | P value |
---|---|---|---|---|
Sex | 1,000 | |||
Female | 58 (29%) | 29 | 29 | |
Male | 142 (71%) | 71 | 71 | |
Age (years) | 60,6 | 58.5 [52.0 - 67.0] | 60.0 [52.0 - 74.0] | 0,154 |
Height (cm) | 173,1 | 175.0 [166.75 - 180.0] | 175.0 [165.0 - 180.0] | 0,463 |
Weight (kg) | 82,6 | 82.0 [75.0 - 90.0] | 80.0 [70.0 - 90.0] | 0,299 |
Body mass index (kg/m2) | 27,5 | 26.8 [25.24 - 29.55] | 26.45 [24.35 - 29.4] | 0,426 |
Body surface area (m2) | 2,0 | 2.0 [1.87 - 2.08] | 1.98 [1.83 - 2.12] | 0,301 |
Heart rate (beats/min) | 78,5 | 77.5 [65.0 - 85.0] | 79.0 [70.0 - 86.25] | 0,035 |
Systolic blood pressure (mmHg) | 141,0 | 140.0 [120.0 - 150.0] | 140.0 [130.0 - 160.0] | 0,131 |
Diastolic blood pressure (mmHg) | 82,4 | 80.0 [70.0 - 90.0] | 80.0 [80.0 - 90.0] | 0,437 |
Vascular risk factors and comorbidities | ||||
Hypertension | 126 (63%) | 65 | 61 | 0,660 |
Diabetes mellitus | 36 (18%) | 17 | 19 | 0,854 |
Family history | 63 (32%) | 32 | 31 | 1,000 |
Kidney function | ||||
Creatinine (micromol/l) | 96,6 | 93.0 [79.0 - 108.25] | 94.0 [81.75 - 106.25] | 0,829 |
Clearance (ml/min) | ||||
>90 | 89 (45%) | 50 | 39 | 0,155 |
60-90 | 80 (40%) | 40 | 40 | 1,000 |
45-59 | 23 (12%) | 7 | 16 | 0,076 |
30-44 | 4 (2%) | 2 | 2 | 1,000 |
15-29 | 4 (2%) | 1 | 3 | 0,614 |
Duration of the symptoms (min) | 304,3 | 120.0 [90.0 - 180.0] | 420.0 [360.0 - 600.0] | 0,000 |
Killip | ||||
1 | 128 (64%) | 72 | 56 | 0,027 |
1/2 | 4 (2%) | 1 | 3 | 0,614 |
2 | 56 (28%) | 24 | 32 | 0,270 |
2/3 | 6 (3%) | 1 | 5 | 0,214 |
3 | 4 (2%) | 0 | 4 | 0,130 |
4 | 2 (1%) | 2 | 0 | 0,477 |
Post MI NYHA status | ||||
1 | 175 (88%) | 89 | 86 | 0,669 |
2 | 18 (9%) | 11 | 7 | 0,459 |
2/3 | 2 (1%) | 0 | 2 | 0,477 |
3 | 1 (0.5%) | 0 | 1 | 1,000 |
4 | 4 (2%) | 0 | 4 | 0,130 |
Post MI CCS | ||||
0 | 188 (94%) | 95 | 93 | 0,766 |
1 | 9 (5%) | 4 | 5 | 1,000 |
2 | 1 (1%) | 0 | 1 | 1,000 |
3 | 1 (1%) | 0 | 1 | 1,000 |
4 | 1 (1%) | 1 | 0 | 1,000 |
Myocardial injury assessment | ||||
Creatine Kinase isoenzyme MB (CKMB) | ||||
Pre-PCI | 61,5 | 27.5 [21.0 - 35.25] | 59.0 [36.0 - 110.0] | 0,000 |
6-hour | 285,1 | 244.0 [122.25 - 376.25] | 345.5 [168.0 - 500.0] | 0,007 |
24-hour | 148,1 | 107.0 [72.25 - 188.0] | 139.5 [81.0 - 194.25] | 0,324 |
72-hour | 38,7 | 30.0 [21.75 - 38.0] | 32.0 [25.0 - 45.0] | 0,040 |
Troponin I (TnI) | ||||
Pre-PCI | 1,4 | 0.04 [0.01 - 0.2] | 1.29 [0.37 - 3.46] | 0,000 |
6-hour | 17,7 | 11.43 [5.26 - 29.2] | 25.0 [10.1 - 30.0] | 0,000 |
24-hour | 12,9 | 7.65 [3.3 - 14.89] | 10.42 [5.5 - 16.9] | 0,575 |
72-hour | 3,4 | 2.21 [1.04 - 3.64] | 3.1 [1.2 - 4.77] | 0,074 |
In-hospital stay length (days) | 6,2 | 6.0 [5.0 - 7.0] | 5.0 [5.0 - 7.0] | 0,265 |
Intrahospital complications | 0 (0%) | 0 | 0 | 1,000 |
Without | 176 (88%) | 88 | 88 | 1,000 |
Ventricular thrombus | 4 (2%) | 2 | 2 | 1,000 |
Pericardial effusion | 5 (3%) | 1 | 4 | 0,365 |
Ventricular fibrillation | 11 (6%) | 8 | 3 | 0,215 |
Pulseless electrical activity | 1 (1%) | 1 | 0 | 1,000 |
Cardiac tamponade | 1 (1%) | 0 | 1 | 1,000 |
Stroke | 1 (1%) | 0 | 1 | 1,000 |
In-hospital death | 1 (1%) | 0 | 1 | 1,000 |
Echocardiographic assessment | ||||
In-hospital FSLV | 35,0 | 34.7 [29.55 - 38.42] | 35.95 [32.6 - 40.15] | 0,254 |
In-hospital EFLV | 48,9 | 50.0 [46.0 - 55.0] | 48.0 [42.0 - 55.0] | 0,024 |
In-hospital LVIDs | 3,2 | 3.2 [2.9 - 3.5] | 3.15 [2.8 - 3.5] | 0,647 |
In-hospital LVIDd | 4,9 | 4.9 [4.6 - 5.2] | 4.9 [4.6 - 5.22] | 0,823 |
In-hospital LVEDV | 102,0 | 94.0 [84.0 - 115.25] | 97.0 [78.5 - 121.5] | 0,787 |
In-hospital LVESV | 52,6 | 48.0 [40.88 - 60.0] | 50.0 [36.25 - 65.0] | 0,727 |
In-hospital MADd | 3,0 | 3.0 [2.9 - 3.2] | 3.0 [2.9 - 3.1] | 0,374 |
In-hospital mitral regurgitation | ||||
0 | 59 (30%) | 26 | 33 | 0,352 |
0/1 | 5 (3%) | 4 | 1 | 0,365 |
1 | 64 (32%) | 38 | 26 | 0,095 |
1/2 | 31 (16%) | 11 | 20 | 0,118 |
2 | 34 (17%) | 19 | 15 | 0,572 |
2/3 | 7 (4%) | 2 | 5 | 0,442 |
Variables | Whole sample (N = 200) | Symptoms duration of less than 6 hours (N = 100) | Symptoms duration of more than 6 hours (N = 100) | P value |
---|---|---|---|---|
Dynamics of the QRS complex | ||||
Pre-PCI QRS width | 100,5 | 100.0 [90.0 - 110.0] | 100.0 [93.5 - 110.0] | 0,463 |
Post-PCI QRS width | 98,8 | 95.0 [85.0 - 100.0] | 100.0 [90.0 - 110.0] | 0,111 |
60-min QRS width | 94,7 | 86.5 [80.0 - 100.0] | 100.0 [87.25 - 100.0] | 0,008 |
72-hour QRS width | 89,8 | 81.0 [80.0 - 90.5] | 95.0 [85.0 - 100.0] | 0,000 |
1-month QRS width | 87,9 | 80.0 [80.0 - 90.0] | 90.0 [85.0 - 100.0] | 0,000 |
6-months QRS width | 87,7 | 80.0 [80.0 - 90.0] | 90.0 [80.0 - 100.0] | 0,000 |
ST-segment elevation (mm) | ||||
Pre-PCI | 3,75 | 3.5 [2.5 - 5.0] | 3.0 [2.0 - 5.0] | 0,064 |
Post-PCI | 1,89 | 1.0 [0.0 - 2.5] | 2.0 [0.5 - 3.0] | 0,051 |
60-min | 1,02 | 0.5 [0.0 - 1.0] | 1.0 [0.0 - 2.0] | 0,005 |
72-hour | 0,47 | 0.0 [0.0 - 0.5] | 0.5 [0.0 - 1.0] | 0,000 |
1-month | 0,18 | 0.0 [0.0 - 0.0] | 0.0 [0.0 - 0.5] | 0,003 |
6-months | 0,14 | 0.0 [0.0 - 0.0] | 0.0 [0.0 - 0.0] | 0,013 |
ST-segment resolution (>50%) | ||||
Post-PCI | 121 (61%) | 72 | 49 | 0,001 |
60-min | 98 (49%) | 48 | 50 | 0,888 |
72-hour | 82 (41%) | 39 | 43 | 0,666 |
1-month | 52 (26%) | 23 | 29 | 0,420 |
6-months | 16 (8%) | 7 | 9 | 0,794 |
Newly formed branch block | ||||
No | 175 (88%) | 87 | 88 | 1,000 |
Transitory RBBB | 2 (1%) | 1 | 1 | 1,000 |
Transitory LBBB | 9 (5%) | 7 | 2 | 0,172 |
Transitory LAHB | 4 (2%) | 2 | 2 | 1,000 |
Permanent LAHB | 5 (3%) | 1 | 4 | 0,365 |
Permanent ILBBB | 2 (1%) | 0 | 2 | 0,477 |
Permanent RBBB | 2 (1%) | 2 | 0 | 0,477 |
Variables | Whole sample (N = 200) | Symptoms duration of less than 6 hours (N = 100) | Symptoms duration of more than 6 hours (N = 100) | P value |
---|---|---|---|---|
6-months follow-up data | ||||
In-hospital death | 1 (1%) | 0 | 1 | 1,000 |
Out-of-hospital death | 5 (3%) | 1 | 4 | 0,365 |
Coronary event-related death | 6 (3%) | 1 | 5 | 0,214 |
Reinfarction of the treated vessel | 1 (1%) | 1 | 0 | 1,000 |
Manifested HF | 28 (14%) | 6 | 22 | 0,002 |
Stent thrombosis | 4 (2%) | 2 | 2 | 1,000 |
Clinically manifested restenosis | 2 (1%) | 0 | 2 | 0,477 |
Ventricular thrombus | 1 (1%) | 1 | 0 | 1,000 |
MACE | 32 (16%) | 9 | 23 | 0,012 |
Dual Antiplatelet Treatment | ||||
Acetylsalicylic acid + Ticagrelor | 79 (40%) | 27 | 52 | 0,001 |
Acetylsalicylic acid + Clopidogrel | 109 (55%) | 69 | 40 | 0,000 |
Acetylsalicylic acid + Ticagrelor + Oral anticoagulant | 2 (1%) | 2 | 0 | 0,477 |
Acetylsalicylic acid + Clopidogrel + Oral anticoagulant | 9 (5%) | 2 | 7 | 0,172 |
Acetylsalicylic acid + Clopidogrel + Direct oral anticoagulant | 1 (1%) | 0 | 1 | 1,000 |
6-months NYHA | ||||
1 | 171 (86%) | 94 | 77 | 0,001 |
1/2 | 1 (1%) | 1 | 0 | 1,000 |
2 | 19 (10%) | 4 | 15 | 0,016 |
2/3 | 1 (1%) | 0 | 1 | 1,000 |
3 | 2 (1%) | 0 | 2 | 0,477 |
3/4 | 1 (1%) | 0 | 1 | 1,000 |
6-months CCS | ||||
0 | 174 (87%) | 86 | 88 | 0,833 |
1 | 13 (7%) | 8 | 5 | 0,566 |
2 | 6 (3%) | 4 | 2 | 0,678 |
3 | 2 (1%) | 1 | 1 | 1,000 |
Echocardiographic assessment | ||||
6-months FSLV | 35,7 | 35.8 [33.3 - 40.0] | 36.0 [32.65 - 39.25] | 0,572 |
6-months EFLV | 51,8 | 55.0 [50.0 - 57.5] | 50.0 [45.0 - 55.0] | 0,000 |
6-months LVIDs | 3,2 | 3.1 [2.8 - 3.45] | 3.2 [2.9 - 3.5] | 0,368 |
6-months LVIDd | 5,0 | 5.0 [4.65 - 5.3] | 5.0 [4.5 - 5.35] | 0,502 |
6-months LVEDV | 104,0 | 95.0 [80.0 - 115.0] | 101.0 [80.5 - 124.0] | 0,251 |
6-months LVESV | 52,3 | 47.0 [37.0 - 52.5] | 50.0 [40.0 - 67.0] | 0,023 |
6-months MADd | 3,1 | 3.1 [3.0 - 3.2] | 3.0 [2.9 - 3.2] | 0,183 |
6-months mitral regurgitation | ||||
0 | 54 (27%) | 28 | 26 | 0,873 |
0/1 | 7 (4%) | 7 | 0 | 0,021 |
1 | 66 (33%) | 36 | 30 | 0,452 |
1/2 | 29 (15%) | 9 | 20 | 0,045 |
2 | 25 (13%) | 13 | 12 | 1,000 |
2/3 | 10 (5%) | 5 | 5 | 1,000 |
3 | 1 (1%) | 0 | 1 | 1,000 |
3/4 | 2 (1%) | 1 | 1 | 1,000 |
6-years follow-up data | ||||
All-cause mortality | 22 (11%) | 7 | 15 | 0,114 |
Cardiovascular death | 14 (7%) | 6 | 8 | 0,782 |
Non-cardiovascular death | 8 (4%) | 1 | 7 | 0,071 |
Hospitalization due to HF | 5 (3%) | 3 | 2 | 1,000 |
Reinfarction | 7 (4%) | 6 | 1 | 0,124 |
Stroke | 4 (2%) | 3 | 1 | 0,614 |
Stent restenosis | 4 (2%) | 2 | 2 | 1,000 |
Re-PCI of the non-culprit vessel | 10 (5%) | 5 | 5 | 1,000 |
Number of days until the first MACE | 1745 | 2287.0 [1874.0 - 2476.0] | 1854.0 [615.0 - 2208.5] | 0,000 |
Number of days until death | 2063 | 2361.0 [2272.5 - 2484.0] | 1942.0 [1601.75 - 2260.5] | 0,000 |
QRS complex | MACE | Width (mm) | P value | OR (95% CI) | P value |
---|---|---|---|---|---|
Pre-PCI | No | 100 (IQR 90-105) | 0.026 | 1.028 (1.003-1.053) | 0.029 |
Yes | 102.5 (IQR 90-110) | ||||
Right after the procedure | No | 95 (IQR 85-100) | 0.010 | 1.026 (1.004-1.048) | 0.020 |
Yes | 100 (IQR 90-110) | ||||
1-hour after the procedure | No | 94 (IQR 85-100) | 0.013 | 1.027 (1.003-1.052) | 0.025 |
Yes | 95 (IQR 85-105) | ||||
72 hours after the procedure | No | 85 (IQR 80-95) | 0.020 | 1.031 (1.002-1.060) | 0.034 |
Yes | 89 (IQR 80-100) | ||||
1 month | No | 85 (IQR 80-90) | 0.034 | 1.042 (1.012-1.074) | 0.007 |
Yes | 85 (IQR 80-100) | ||||
6 months | No | 85 (IQR 80-90) | 0.041 | 1.038 (1.009-1.069) | 0.011 |
Yes | 87.5 (IQR 80-100) |
ST-segment | MACE | Elevation (mm) | P value | OR (95% CI) | P value |
---|---|---|---|---|---|
Pre-PCI | No | 3 (IQR 2-5) | 0.018 | 1.61 (1.024-1.317) | 0.020 |
Yes | 3 (IQR 2.5-5) | ||||
Right after the procedure | No | 1 (IQR 0-2.5) | 0.000 | 1.296 (1.103-1.523) | 0.002 |
Yes | 2 (IQR 0.75-3) | ||||
1-hour after the procedure | No | 0 (IQR 0-1) | 0.000 | 1.391 (1.111-1.741) | 0.004 |
Yes | 0.5 (IQR 0.5-2) | ||||
72 hours after the procedure | No | 0 (IQR 0-5) | 0.004 | 1.500 (1.037-2.170) | 0.031 |
Yes | 0 (IQR 0-0.75) | ||||
1 month | No | 0 (IQR 0-0) | 0.000 | 3.256 (1.572-6.747) | 0.001 |
Yes | 0 (IQR 0-0.5) | ||||
6 months | No | 0 (IQR 0-0) | 0.003 | 2.972 (1.268-6.965) | 0.012 |
Yes | 0 (IQR 0-0.25) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated